

20 January 2025

## Notice of 4Q FY24 Result and Investor Webinar

**Next Science Limited** (ASX:NXS) (“Next Science” or “the Company”) will announce its 4Q FY24 result for the quarter ending 31 December 2024 on Thursday 23 January 2025.

Following the release of the results, CEO and Managing Director, I.V. Hall and CFO Marc Zimmerman, will host a zoom webinar for the investment community.

**Date & time:** Thursday 23 January 2025 at 9.00am (Sydney time)

**Register:** Please follow the link below to register and access dial-in details

[https://us06web.zoom.us/webinar/register/WN\\_Hjla2OIoRZSDd6hs-4tiRQ](https://us06web.zoom.us/webinar/register/WN_Hjla2OIoRZSDd6hs-4tiRQ)

Investors can submit questions prior to the webinar to [fdixon@nextscience.com](mailto:fdixon@nextscience.com) or ask questions via the Q&A function during the webinar.

**Approved and authorised for release by CEO & Managing Director**

### Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: [fdixon@nextscience.com](mailto:fdixon@nextscience.com)

### About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company’s primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: [www.nextscience.com](http://www.nextscience.com)